Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: Efficacy and safety profile of 54 patients at a tertiary referral center in a developing country

Neurology India

Volumn 55, Issue 1, 2007, Pages 46-49

  Padma, M ^a   Singh, M ^a   Bhatia, R ^a   Srivastava, A ^a   Tripathi, M ^a   Shukla, G ^a   Goyal, V ^a   Singh, S ^a   Prasad, K ^a   Behari, M ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

rtPA; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ACITROM; ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ENALAPRIL; GLYCERYL TRINITRATE; HEPARIN; LABETALOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPIRATION; BARTHEL INDEX; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRONTAL LOBE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROTHROMBIN TIME; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT;

EID: 33846946825     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.30426     Document Type: Article

References (14)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
2. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
3. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue - type plasminogen activator for acute ischemic stroke: A Cleveland update. Stroke 2003;34:799-800.
4. Kaste M. Thrombolysis in ischemic stroke - present and future: Role of combined therapy. Cerebrovasc Dis 2001;11:55-9.
5. Practice advisory: Thrombolytic therapy for acute ischemic stroke - summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835-9.
6. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167-74.
7. Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederksen SM. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: A retrospective analysis. Acad Emerg Med 1999;6:618-25.
8. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002;162:1994-2001.
9. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey. The t - PA Stroke Survey Group. Neurology 1999;53:424-7.
10. Clark WM, Lutsep HL. Medical treatment strategies: Intra-venous thrombolysis, neuronal protection and anti-reperfusion injury agents. Neuroimaging Clin N Am 1999;9:465-73.
11. Akins PT, Delemos C, Wentworth D, Byer J, Schorer SJ, Atkinson RP. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 2000;55:1801-5.
12. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000;31:77-81.
13. Koenneeke HC, Nohr R, Leister S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety and efficacy in a single - center, 2 - year experience. Stroke 2001;32:1074-8.
14. Schmulling S, Grand M, Rudolf J, Heis WD. One - year follow - up in acute stroke patients treated with rt - PA in clinical routine. Stroke 2000;31:1552-4.